 Connection
Jeffrey Kern to Humans
This is a "connection" page, showing publications Jeffrey Kern has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.312 |
|
|
|
-
Wisnivesky JP, Mudd J, Stone K, Slatore CG, Flores R, Swanson S, Blackstock W, Smith CB, Chidel M, Rosenzweig K, Henschke C, Kern JA. Longitudinal quality of life after sublobar resection and stereotactic body radiation therapy for early-stage non-small cell lung cancer. Cancer. 2024 Jul 15; 130(14):2515-2527.
Score: 0.023
-
Goleva E, Lyubchenko T, Kraehenbuehl L, Lacouture ME, Leung DYM, Kern JA. Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy. Ann Allergy Asthma Immunol. 2021 06; 126(6):630-638.
Score: 0.019
-
Kern JA, Kim J, Foster DG, Mishra R, Gardner EE, Poirier JT, Rivard C, Yu H, Finigan JH, Dowlati A, Rudin CM, Tan AC. Role of mTOR As an Essential Kinase in SCLC. J Thorac Oncol. 2020 09; 15(9):1522-1534.
Score: 0.018
-
Leach SM, Finigan J, Vasu VT, Mishra R, Ghosh M, Foster D, Mason R, Kosmider B, Farias Hesson E, Kern JA. The Kinome of Human Alveolar Type II and Basal Cells, and Its Reprogramming in Lung Cancer. Am J Respir Cell Mol Biol. 2019 10; 61(4):481-491.
Score: 0.017
-
Mishra R, Foster DG, Finigan JH, Kern JA. Interleukin-6 is required for Neuregulin-1 induced HER2 signaling in lung epithelium. Biochem Biophys Res Commun. 2019 06 11; 513(4):794-799.
Score: 0.016
-
Carr LL, Chung JH, Duarte Achcar R, Lesic Z, Rho JY, Yagihashi K, Tate RM, Swigris JJ, Kern JA. The clinical course of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. Chest. 2015 Feb; 147(2):415-422.
Score: 0.012
-
Finigan JH, Vasu VT, Thaikoottathil JV, Mishra R, Shatat MA, Mason RJ, Kern JA. HER2 activation results in ?-catenin-dependent changes in pulmonary epithelial permeability. Am J Physiol Lung Cell Mol Physiol. 2015 Jan 15; 308(2):L199-207.
Score: 0.012
-
Randall TD, Kern JA. Tertiary lymphoid structures target the antitumor immune response to lung cancer. Am J Respir Crit Care Med. 2014 Apr 01; 189(7):767-9.
Score: 0.012
-
Finigan JH, Kern JA. Lung cancer screening: past, present and future. Clin Chest Med. 2013 Sep; 34(3):365-71.
Score: 0.011
-
Finigan JH, Downey GP, Kern JA. Human epidermal growth factor receptor signaling in acute lung injury. Am J Respir Cell Mol Biol. 2012 Oct; 47(4):395-404.
Score: 0.010
-
Finigan JH, Mishra R, Vasu VT, Silveira LJ, Nethery DE, Standiford TJ, Burnham EL, Moss M, Kern JA. Bronchoalveolar lavage neuregulin-1 is elevated in acute lung injury and correlates with inflammation. Eur Respir J. 2013 Feb; 41(2):396-401.
Score: 0.010
-
Carr L, Kern JA. Computed tomography screening for lung cancer: the challenge of what and how. Am J Respir Crit Care Med. 2012 Jan 01; 185(1):8-10.
Score: 0.010
-
Carr LL, Finigan JH, Kern JA. Evaluation and treatment of patients with non-small cell lung cancer. Med Clin North Am. 2011 Nov; 95(6):1041-54.
Score: 0.010
-
Kolosova I, Nethery D, Kern JA. Role of Smad2/3 and p38 MAP kinase in TGF-?1-induced epithelial-mesenchymal transition of pulmonary epithelial cells. J Cell Physiol. 2011 May; 226(5):1248-54.
Score: 0.009
-
Finigan JH, Faress JA, Wilkinson E, Mishra RS, Nethery DE, Wyler D, Shatat M, Ware LB, Matthay MA, Mason R, Silver RF, Kern JA. Neuregulin-1-human epidermal receptor-2 signaling is a central regulator of pulmonary epithelial permeability and acute lung injury. J Biol Chem. 2011 Mar 25; 286(12):10660-70.
Score: 0.009
-
Dowlati A, Kluge A, Nethery D, Halmos B, Kern JA. SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2. Anticancer Drugs. 2008 Jan; 19(1):9-16.
Score: 0.007
-
Nethery DE, Ghosh S, Erzurum SC, Kern JA. Inactivation of neuregulin-1 by nitration. Am J Physiol Lung Cell Mol Physiol. 2007 Jan; 292(1):L287-93.
Score: 0.007
-
Nethery DE, Moore BB, Minowada G, Carroll J, Faress JA, Kern JA. Expression of mutant human epidermal receptor 3 attenuates lung fibrosis and improves survival in mice. J Appl Physiol (1985). 2005 Jul; 99(1):298-307.
Score: 0.006
-
Lacouture ME, Goleva E, Shah N, Rotemberg V, Kraehenbuehl L, Ketosugbo KF, Merghoub T, Maier T, Bang A, Gu S, Salvador T, Moy AP, Lyubchenko T, Xiao O, Hall CF, Berdyshev E, Crooks J, Weight R, Kern JA, Leung DYM. Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways. Clin Cancer Res. 2024 Jul 01; 30(13):2822-2834.
Score: 0.006
-
Dowlati A, Nethery D, Kern JA. Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. Mol Cancer Ther. 2004 Apr; 3(4):459-63.
Score: 0.006
-
Gollamudi M, Nethery D, Liu J, Kern JA. Autocrine activation of ErbB2/ErbB3 receptor complex by NRG-1 in non-small cell lung cancer cell lines. Lung Cancer. 2004 Feb; 43(2):135-43.
Score: 0.006
-
Kern JA. Sounding the mediastinum. Am J Respir Crit Care Med. 2003 Dec 01; 168(11):1261-2.
Score: 0.006
-
Wang Q, Stone K, Kern JA, Slatore CG, Swanson S, Blackstock W, Khan RS, Smith CB, Veluswamy RR, Chidel M, Wisnivesky JP. Adverse Events Following Limited Resection versus Stereotactic Body Radiation Therapy for Early Stage Lung Cancer. Ann Am Thorac Soc. 2022 12; 19(12):2053-2061.
Score: 0.005
-
Liu J, Kern JA. Neuregulin-1 activates the JAK-STAT pathway and regulates lung epithelial cell proliferation. Am J Respir Cell Mol Biol. 2002 Sep; 27(3):306-13.
Score: 0.005
-
Croft DR, Trapp J, Kernstine K, Kirchner P, Mullan B, Galvin J, Peterson MW, Gross T, McLennan G, Kern JA. FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence. Lung Cancer. 2002 Jun; 36(3):297-301.
Score: 0.005
-
Wang EA, Goleva E, Ketosugbo K, Kern JA, Kraehenbuehl L, Lacouture ME, Leung DYM. Effect of immune checkpoint inhibitors on asthma. Ann Allergy Asthma Immunol. 2022 08; 129(2):257-258.
Score: 0.005
-
Luo J, Beattie JA, Fuentes P, Rizvi H, Egger JV, Kern JA, Leung DYM, Lacouture ME, Kris MG, Gambarin M, Santomasso BD, Faleck DM, Hellmann MD. Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events. J Thorac Oncol. 2021 10; 16(10):1759-1764.
Score: 0.005
-
Wang E, Kraehenbuehl L, Ketosugbo K, Kern JA, Lacouture ME, Leung DYM. Immune-related cutaneous adverse events due to checkpoint inhibitors. Ann Allergy Asthma Immunol. 2021 06; 126(6):613-622.
Score: 0.005
-
Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP, Kern JA, Lacouture ME. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020 Nov; 83(5):1255-1268.
Score: 0.004
-
Bruno TC, Ebner PJ, Moore BL, Squalls OG, Waugh KA, Eruslanov EB, Singhal S, Mitchell JD, Franklin WA, Merrick DT, McCarter MD, Palmer BE, Kern JA, Slansky JE. Antigen-Presenting Intratumoral B Cells Affect CD4+ TIL Phenotypes in Non-Small Cell Lung Cancer Patients. Cancer Immunol Res. 2017 10; 5(10):898-907.
Score: 0.004
-
Carr LL, Kern JA, Deutsch GH. Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia and Neuroendocrine Hyperplasia of Infancy. Clin Chest Med. 2016 09; 37(3):579-87.
Score: 0.003
-
Carr LL, Zelarney P, Meadows S, Kern JA, Long MB, Kern E. Development of a Cancer Care Summary Through the Electronic Health Record. J Oncol Pract. 2016 Feb; 12(2):e231-40.
Score: 0.003
-
Kim J, Vasu VT, Mishra R, Singleton KR, Yoo M, Leach SM, Farias-Hesson E, Mason RJ, Kang J, Ramamoorthy P, Kern JA, Heasley LE, Finigan JH, Tan AC. Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy. Bioinformatics. 2014 Sep 01; 30(17):2393-8.
Score: 0.003
-
Guin S, Ru Y, Wynes MW, Mishra R, Lu X, Owens C, Barn AE, Vasu VT, Hirsch FR, Kern JA, Theodorescu D. Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression. J Thorac Oncol. 2013 Dec; 8(12):1492-501.
Score: 0.003
-
Tuder RM, Kern JA, Miller YE. Senescence in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2012 May; 9(2):62-3.
Score: 0.003
-
Kluge A, Dabir S, Kern J, Nethery D, Halmos B, Ma P, Dowlati A. Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer. Int J Cancer. 2009 Oct 01; 125(7):1728-34.
Score: 0.002
-
Thaiyananthan NN, Jacono FJ, Patel SR, Kern JA, Stoller JK. Right-to-left anatomic shunt associated with a persistent left superior vena cava: the importance of injection site in demonstrating the shunt. Chest. 2009 Aug; 136(2):617-620.
Score: 0.002
-
Kratzke RA, Wang X, Wong L, Kratzke MG, Green MR, Vokes EE, Vogelzang NJ, Kindler HL, Kern JA. Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904. J Thorac Oncol. 2008 Apr; 3(4):417-21.
Score: 0.002
-
Yu Z, Boggon TJ, Kobayashi S, Jin C, Ma PC, Dowlati A, Kern JA, Tenen DG, Halmos B. Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. Cancer Res. 2007 Nov 01; 67(21):10417-27.
Score: 0.002
-
Cortas T, Eisenberg R, Fu P, Kern J, Patrick L, Dowlati A. Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer. Lung Cancer. 2007 Mar; 55(3):349-55.
Score: 0.002
-
Clamon G, Herndon J, Kern J, Govindan R, Garst J, Watson D, Green M. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. Cancer. 2005 Apr 15; 103(8):1670-5.
Score: 0.002
-
D'Cunha J, Herndon JE, Herzan DL, Patterson GA, Kohman LJ, Harpole DH, Kernstine KH, Kern JA, Green MR, Maddaus MA, Kratzke RA. Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial. Lung Cancer. 2005 May; 48(2):241-6.
Score: 0.002
-
Vollmer RT, Herndon JE, D'Cunha J, Abraham NZ, Solberg J, Fatourechi M, Maruska A, Kern JA, Green MR, Kratzke RA, Maddaus MA. Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: anatomical pathology results from Cancer and Leukemia Group B Trial 9761. Clin Cancer Res. 2003 Nov 15; 9(15):5630-5.
Score: 0.001
-
Vermeer PD, Einwalter LA, Moninger TO, Rokhlina T, Kern JA, Zabner J, Welsh MJ. Segregation of receptor and ligand regulates activation of epithelial growth factor receptor. Nature. 2003 Mar 20; 422(6929):322-6.
Score: 0.001
-
D'Cunha J, Corfits AL, Herndon JE, Kern JA, Kohman LJ, Patterson GA, Kratzke RA, Maddaus MA. Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer--preliminary results of Cancer and Leukemia Group B Trial 9761. J Thorac Cardiovasc Surg. 2002 Mar; 123(3):484-91; discussion 491.
Score: 0.001
-
Johnson EA, Klimstra DS, Herndon JE, Catalano E, Canellos GP, Graziano SL, Kern JA, Green MR. Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer. Cancer Invest. 2002; 20(5-6):686-92.
Score: 0.001
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|